Abstract

A neutrophil chemotactic factor N-formyl-methionyl-leucyl-phenylalanine (fMLP), produced by Escherichia coli under conditions of intestinal inflammation, is reported to circulate enterohepatically in the presence of experimental colitis, but its effect on bile secretion is unclear. Therefore, we investigated the effect of fMLP on bile secretion in a single-pass isolated perfused rat liver system. Infusion of fMLP at different concentrations (2 micromol/L, 10 micromol/L, and 20 micromol/L) into the portal vein resulted in excretion into bile in the native form, independent of sodium taurocholate (1 micromol/min) infusion. Excretion of fMLP increased dose dependently, and approximately 12% of the infused dose was detected at each concentration. With constant infusion of sodium taurocholate (1 micromol/min), fMLP (20 micromol/L) increased bile flow but decreased phospholipid and cholesterol secretion. Bile acid secretion was not affected. Phospholipid/bile acid molar ratios decreased from 0.069 +/- 0.002 to 0.038 +/- 0.002, and cholesterol/bile acid molar ratios decreased from 0.0074 +/- 0.0009 to 0.0029 +/- 0.0008. Thus, administration of fMLP resulted in the uncoupling of biliary excretion of phospholipid and cholesterol from that of bile acids; this effect proved reversible. The increase in bile flow caused by fMLP infusion appeared to result from osmotic choleresis. When 25 mg of horseradish peroxidase, a conventional marker of transcytotic vesicle transport pathway, was infused for 1 minute as a pulse load into the portal vein after continuous infusion of taurocholate, its late peak excretion was reduced by fMLP (10 micromol/L) from 9.59 +/- 1.09 to 6.05 +/- 0.66 (ng/g liver). Gel-permeation chromatography of bile showed a specific association of fMLP with bile acids. These results suggest an uncoupling of biliary lipids from bile acids by fMLP because of inhibition of transcellular vesicle transport and interaction between fMLP and bile acid micelles in the bile canaliculus. (Hepatology 1996 Nov;24(5):1224-9)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.